Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

Blood - 18 Feb 2010

Pratz Keith W, Sato Takashi, Murphy Kathleen M, Stine Adam, Rajkhowa Trivikram, Levis Mark

Abstract excerpt

We examined 6 different FMS-like tyrosine kinase-3 (FLT3) inhibitors (lestaurtinib, midostaurin, AC220, KW-2449, sorafenib, and sunitinib) for potency against mutant and wild-type FLT3, as well as for cytotoxic effect against a series of primary blast samples obtained from patients with acute myeloid leukemia (AML) harboring internal tandem duplication (FLT3/ITD) mutations. We found that inhibition of FLT3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antineoplastic Agents
Share to Cell Death

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Drug Resistance, Neoplasm

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Phosphorylation

Source

Open in PubMed Open full text

Identifiers

PMID: 20007803
DOI: 10.1182/blood-2009-09-242859
PMCID: PMC2826764

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.PMID 20007803Read ↗

FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging ControversiesSemantic proximity Read ↗

FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.Semantic proximity Read ↗

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia.Semantic proximity Read ↗

Prognostic value of the mutation types and dynamics of FLT3-ITD in acute myeloid leukemia.Semantic proximity Read ↗

FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.Semantic proximity Read ↗

Clinical and molecular response of AML harboring non-canonical <i>FLT3</i> N676K driver mutations to contemporary FLT3 inhibitorsSemantic proximity Read ↗

Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.Semantic proximity Read ↗

FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Semantic proximity Read ↗

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML.Semantic proximity Read ↗

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.Semantic proximity Read ↗

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.Semantic proximity Read ↗

Inhibition of FLT3 in AML: a focus on sorafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.